EN DE
STOCK COMPARISON

Hanmi Science vs McKesson: Fair Value & Quality

Both stocks run through our valuation models. Here is how Hanmi Science (008930) and McKesson (MCK) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: Hanmi Science trades at KRW 44,650 versus a fair value of KRW 29,718 (-33%), while McKesson trades at $870 versus $819 (-6%).
Hanmi Science
008930.KO · KRW · Health Care
-33%
upside to fair value
overvalued
PriceKRW 44,650
Fair ValueKRW 29,718
Quality57/100
McKesson
MCK · USD · Health Care
-6%
upside to fair value
fairly valued
Price$870
Fair Value$819
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Hanmi ScienceMcKesson
Valuation
—P/E (TTM)21.0×
—P/S (TTM)0.23×
—EV/EBITDA13.9×
—PEG1.57×
0.9%Dividend yield0.4%
KRW 300Dividend per share$3.17
Profitability
10%Net margin1%
9%Operating margin2%
15%Return on equity—
3%Return on assets5%
Growth
7%Revenue growth (YoY)6%
9.1%Avg. growth/yr (3Y)13.4%
9.6%Avg. growth/yr (5Y)11.1%
Balance & size
$2BMarket cap$94B
expensiveGrowth qualityhealthy

Hanmi Science leads: 4 to 3 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Hanmi Scienceof which business quality 55 · market factors 46 McKessonof which business quality 65 · market factors 63
ProfitabilityMargins and returns on capital today
51
49
Quality GrowthAre margins and returns improving?
58
65
CashflowEarnings quality: real cash, not paper profit
21
47
Fin. StrengthBalance sheet, leverage, solvency risk
71
72
InvestmentDisciplined investing over empire-building
66
76
Low VolatilityCalm price path (market factor)
52
83
MomentumPrice trend over the last 3–12 months (market factor)
42
51
52W MomentumDistance to the 52-week high (market factor)
45
62
Net IssuanceBuybacks instead of dilution
79
100

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Hanmi Science

DCF ModelsKRW 21,759
Earnings-BasedKRW 41,587
MultiplesKRW 22,948
Asset-BasedKRW 9,517
Growth DCFKRW 16,875
Economic ProfitKRW 13,616
Growth EarningsKRW 55,141

19 of 24 models see the stock below the current price.

McKesson

DCF Models$955
Earnings-Based$444
Dividend Discount$57.26
Multiples$848
Growth DCF$922
Economic Profit$497
Growth Earnings$708

13 of 23 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Hanmi Science
Bear KRW 13,925Fair Value KRW 29,718Bull KRW 38,486
KRW 44,650 = current price (white tick)
McKesson
Bear $605Fair Value $819Bull $1,034
$870 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Hanmi Science · Health Care

Quality score57 · above median
Fair value upside-33% · below median

McKesson · Health Care

Quality score66 · Top 25%
Fair value upside-6% · above median

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: Hanmi Science trades at KRW 44,650 versus a fair value of KRW 29,718 (-33%), while McKesson trades at $870 versus $819 (-6%).

McKesson has the higher quality score (66/100).

See the full analysis →
Hanmi Science · McKesson

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Hanmi Science

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to McKesson

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.